Drug Profile


Alternative Names: ASP-3550; Degarelix acetate; FE-200486; Firmagon; Gonax; Uglypeptide-1

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Astellas Pharma; Ferring Pharmaceuticals
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 01 Jun 2017 Ferring Pharmaceuticals completes a phase III trial in Prostate cancer in Finland, France and Germany(NCT02526784)
  • 01 May 2017 Ferring Pharmaceuticals completes a phase III extension trial for Prostate cancer in China (NCT02015871)
  • 07 Oct 2016 Efficacy data from the pooled analysis of phase III trials in Prostate cancer presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top